Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Study Design and Selection of Patients
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bahakel, H.; Feldman, A.G.; Danziger-Isakov, L. Immunization of Solid Organ Transplant Candidates and Recipients: A 2022 Update. Infect. Dis. Clin. N. Am. 2023. [Google Scholar] [CrossRef] [PubMed]
- Toniutto, P.; Germani, G.; Ferrarese, A.; Bitetto, D.; Zanetto, A.; Fornasiere, E.; Fumolo, E.; Shalaby, S.; Burra, P. An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. Am. J. Med. 2022, 135, 157–166. [Google Scholar] [CrossRef]
- Fagiuoli, S.; Colli, A.; Bruno, R.; Craxi, A.; Gaeta, G.B.; Grossi, P.; Mondelli, M.U.; Puoti, M.; Sagnelli, E.; Stefani, S.; et al. Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. J. Hepatol. 2014, 60, 1075–1089. [Google Scholar] [CrossRef] [PubMed]
- Javaid, H.; Prasad, P.; De Golovine, A.; Hasbun, R.; Jyothula, S.; Machicao, V.; Bynon, J.S.; Ostrosky, L.; Nigo, M. Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus and Seroresponse to the Vaccinations in Adult Solid Organ Transplant Candidates. Transplantation 2023. [Google Scholar] [CrossRef] [PubMed]
- Alukal, J.J.; Naqvi, H.A.; Thuluvath, P.J. Vaccination in Chronic Liver Disease: An Update. J. Clin. Exp. Hepatol. 2022, 12, 937–947. [Google Scholar] [CrossRef]
- Valour, F.; Conrad, A.; Ader, F.; Launay, O. Vaccination in adult liver transplantation candidates and recipients. Clin. Res. Hepatol. Gastroenterol. 2020, 44, 126–134. [Google Scholar] [CrossRef]
- Yoo, J.J.; Yon, D.K.; Lee, S.W.; Shin, J.I.; Kim, B.K. Humoral Immunogenicity to SARS-CoV-2 Vaccination in Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Int. J. Biol. Sci. 2022, 18, 5849–5857. [Google Scholar] [CrossRef]
- Cheung, K.S.; Mok, C.H.; Mao, X.; Zhang, R.; Hung, I.F.; Seto, W.K.; Yuen, M.F. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis. Clin. Mol. Hepatol. 2022, 28, 890–911. [Google Scholar] [CrossRef]
- Toniutto, P.; Cussigh, A.; Cmet, S.; Bitetto, D.; Fornasiere, E.; Fumolo, E.; Fabris, M.; D’Aurizio, F.; Fabris, C.; Grillone, L.; et al. Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients. Liver Int. 2022, 43, 452–461. [Google Scholar] [CrossRef]
- Perrier, Q.; Lupo, J.; Gerster, T.; Augier, C.; Falque, L.; Rostaing, L.; Pelletier, L.; Bedouch, P.; Blanc, M.; Saint-Raymond, C.; et al. SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients. Vaccine 2022, 40, 6404–6411. [Google Scholar] [CrossRef]
- Meunier, L.; Sanavio, M.; Dumortier, J.; Meszaros, M.; Faure, S.; Ursic Bedoya, J.; Echenne, M.; Boillot, O.; Debourdeau, A.; Pageaux, G.P. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients. Liver Int. 2022, 42, 1872–1878. [Google Scholar] [CrossRef]
- Harberts, A.; Schaub, G.M.; Ruether, D.F.; Duengelhoef, P.M.; Brehm, T.T.; Karsten, H.; Fathi, A.; Jahnke-Triankowski, J.; Fischer, L.; Addo, M.M.; et al. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients. Clin. Gastroenterol. Hepatol. 2022, 20, 2558–2566.e5. [Google Scholar] [CrossRef] [PubMed]
- Zecca, E.; Rizzi, M.; Tonello, S.; Matino, E.; Costanzo, M.; Rizzi, E.; Casciaro, G.F.; Manfredi, G.F.; Acquaviva, A.; Gagliardi, I.; et al. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. Viruses 2022, 14, 1766. [Google Scholar] [CrossRef] [PubMed]
- Boyarsky, B.J.; Werbel, W.A.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA 2021, 325, 1784–1786. [Google Scholar] [CrossRef] [PubMed]
- Charlton, M.; Levitsky, J.; Aqel, B.; O’Grady, J.; Hemibach, J.; Rinella, M.; Fung, J.; Ghabril, M.; Thomason, R.; Burra, P.; et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 2018, 102, 727–743. [Google Scholar] [CrossRef]
- Connolly, C.M.; Chiang, T.P.; Boyarsky, B.J.; Ruddy, J.A.; Teles, M.; Alejo, J.L.; Massie, A.; Werbel, W.A.; Shah, A.A.; Christopher-Stine, L.; et al. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: A case series. Ann. Rheum. Dis. 2022, 81, 293–295. [Google Scholar] [CrossRef]
- Regele, F.; Heinzel, A.; Hu, K.; Raab, L.; Eskandary, F.; Fae, I.; Zelzer, S.; Bohmig, G.A.; Bond, G.; Fischer, G.; et al. Stopping of Mycophenolic Acid in Kidney Transplant Recipients for 2 Weeks Peri-Vaccination Does Not Increase Response to SARS-CoV-2 Vaccination-A Non-randomized, Controlled Pilot Study. Front. Med. 2022, 9, 914424. [Google Scholar] [CrossRef]
- Meunier, L.; Malezieux, E.; Ursic Bedoya, J.; Faure, S.; Echenne, M.; Debourdeau, A.; Meszaros, M.; Pageaux, G.P. Mycophenolate mofetil discontinuation increases severe acute respiratory syndrome coronavirus 2 vaccine response in nonresponder liver transplantation recipients: A proof of concept. Liver Transpl. 2023, 29, 114–117. [Google Scholar] [CrossRef]
- Alejo, J.L.; Chiang, T.P.Y.; Bowles Zeiser, L.; Kim, J.D.; Mitchell, J.; Avery, R.K.; Tobian, A.A.R.; Abedon, R.R.; Levan, M.L.; Warren, D.S.; et al. Incidence and Severity of COVID-19 Among Vaccinated Solid Organ Transplant Recipients During the Omicron Wave. Transplantation 2022, 106, e413–e415. [Google Scholar] [CrossRef]
- Karaba, A.H.; Johnston, T.S.; Aytenfisu, T.Y.; Akinde, O.; Eby, Y.; Ruff, J.E.; Abedon, A.T.; Alejo, J.L.; Blankson, J.N.; Cox, A.L.; et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation 2022, 106, 1440–1444. [Google Scholar] [CrossRef] [PubMed]
- Bonifacio, M.A.; Laterza, R.; Vinella, A.; Schirinzi, A.; Defilippis, M.; Di Serio, F.; Ostuni, A.; Fasanella, A.; Mariggio, M.A. Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection. Int. J. Mol. Sci. 2022, 23, 9566. [Google Scholar] [CrossRef] [PubMed]
- Alejo, J.L.; Mitchell, J.; Chiang, T.P.; Abedon, A.T.; Boyarsky, B.J.; Avery, R.K.; Tobian, A.A.R.; Levan, M.L.; Massie, A.B.; Garonzik-Wang, J.M.; et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation 2021, 105, e280–e281. [Google Scholar] [CrossRef]
- Kamar, N.; Abravanel, F.; Marion, O.; Romieu-Mourez, R.; Couat, C.; Del Bello, A.; Izopet, J. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. JAMA Netw. Open 2021, 4, e2136030. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, J.; Alejo, J.L.; Chiang, T.P.Y.; Kim, J.; Chang, A.; Abedon, A.T.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Levan, M.L.; et al. Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update. Transplantation 2022, 106, e338–e340. [Google Scholar] [CrossRef] [PubMed]
Patients | |||||
---|---|---|---|---|---|
Sex | F | M | F | M | M |
Age (years) | 70 | 75 | 50 | 68 | 78 |
Time from LT (months) | 31.8 | 83.9 | 19.0 | 22.5 | 314.4 |
Etiology of liver disease | PBC | HCV | AIH | AH | HBV |
Immunosuppressive daily dose or drug levels | |||||
Mycophenolate mofetil (g/day) § | 2 | 2 | 1 | 1 | 2 |
Tacrolimus (ng/mL) | 4.82 | 4.64 | 6.49 | 4.76 | 3.40 |
Neutrophils (n ∗ 1000/µL) [2.0–7.50] | 1.39 | 4.07 | 4.13 | 1.71 | 2.68 |
Lymphocytes (n ∗ 1000/µL) [1.0–4.0] | 2.21 | 0.70 | 3.72 | 0.85 | 1.75 |
Platelets (n ∗ 1000/µL) [150–400] | 266 | 204 | 506 | 114 | 227 |
AST (U/mL) [f: 4–32, m: 4–40] | 20 | 12 | 23 | 12 | 16 |
ALT (U/mL) [f: 4–33, m: 4–41] | 22 | 10 | 15 | 12 | 9 |
Bilirubin (mg/dl) [0.20–1.0] | 0.56 | 0.27 | 1.35 | 0.39 | 0.91 |
Albumin (g/dl) [4.02–4.76] | 4.51 | 4.03 | 3.49 | 4.45 | 4.53 |
eGFR (mL/min/1.73 m2) | 46 | 31 | 62 | 39 | 33 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Toniutto, P.; Cussigh, A.; Cmet, S.; Fabris, M.; Curcio, F.; Bitetto, D.; Fornasiere, E.; Fumolo, E.; Falleti, E. Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients. Vaccines 2023, 11, 1165. https://doi.org/10.3390/vaccines11071165
Toniutto P, Cussigh A, Cmet S, Fabris M, Curcio F, Bitetto D, Fornasiere E, Fumolo E, Falleti E. Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients. Vaccines. 2023; 11(7):1165. https://doi.org/10.3390/vaccines11071165
Chicago/Turabian StyleToniutto, Pierluigi, Annarosa Cussigh, Sara Cmet, Martina Fabris, Francesco Curcio, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, and Edmondo Falleti. 2023. "Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients" Vaccines 11, no. 7: 1165. https://doi.org/10.3390/vaccines11071165